Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. The findings were presented today at the IASLC 2026 World Conference on…
The ARTEMIS-008 trial, a randomized Phase III study involving 461 patients from China, has demonstrated that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improves overall survival for patients with relapsed small-cell lung cancer (SCLC) who have progressed after platinum-based chemotherapy, compared to topotecan.
At the IASLC 2026 World Conference on Lung Cancer, researchers presented that Ris-Rez extended median overall survival from 18.5 months with the drug to 10.3 months with topotecan, a 54% reduction in death risk (HR 0.46; 95% CI, 0.35--0.62; P 0.0001). The drug reduced the progression-free survival from 7.2 months with Ris-Rez to 3.0 months with topotecan (HR 0.33; 95% CI, 0.25--0.42), increased the objective response rate from 12.6% with topotecan to 58.3% with Ris-Rez, and improved disease control from 60.2% to 90.4%.
Ris-Rez also showed a better safety profile, with fewer patients experiencing grade 3 or higher treatment-related adverse events (60.9% vs 78.2%).
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
